OR WAIT null SECS
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Activation and expansion are essential for success in both autologous and allogeneic therapies.
Continuous manufacturing and a quality-by-design development approach are a natural fit.
September 03, 2022
The flow of capital and scientific acuity irrigates this pharm system.
Biopharmaceutical manufacturers must consider a surprisingly wide range of factors when deciding where to turn for assistance with cell line development.
It is argued that orthogonal quantitative methods can be used to establish primary working standards. An example details how to calculate the expanded measurement uncertainty (U) for the certified assay value by considering two orthogonal assay methods.
API permeation into the skin modulates the efficacy of topical treatments.
It is possible to overcome some of the limitations of traditional dosage forms by employing alternative drug delivery formulation strategies.
August 31, 2022
Forecyte Bio and Cytiva will team up to accelerate the development and manufacturing of cell and gene therapies.
Pharmaceutical Technology spoke with Andrew Anderson, Global Head Strategic Account Management and Mary Todas, Director Technical Development and Regulatory Affairs, both with Pfizer CentreOne, about best practices for API quality.
August 30, 2022
Scientists have developed a mouse model that could be a promising model system for research into factors affecting mammalian embryonic development and disease.
August 22, 2022
ProBioGen will collobarate with NextPoint Therapeutics to develop and manufacture its lead antibody candidate.
August 16, 2022
In this episode of the Drug Solutions Podcast, John Koleng, VP of product development and manufacturing for TFF Pharmaceuticals shares outsourcing strategies in biopharma.